OBJECTIVE: To test the hypothesis that combined administration of multiple doses of nebulised salbutamol and magnesium sulphate provides additional benefit compared with salbutamol alone in adult patients with acute asthma. DESIGN: Randomised, double blind, prospective study. METHODS: A total of 100 patients presenting to an emergency department with an acute attack of bronchial asthma were randomised to two groups: nebulisation with a combination of salbutamol and magnesium sulphate (group A) and nebulisation with salbutamol only (group B). Both groups received nebulisation thrice at intervals of 20 minutes. Salbutamol and magnesium sulphate were administered in doses of 0.5 mg and 500 mg, respectively, and the solutions were made isotonic to plasma osmolality. Pulse rate, blood pressure, and peak expiratory flow rate (PEFR) were measured at baseline and at 15, 60, 75, and 120 minutes. Serum magnesium levels and blood gases were measured at 0 and 120 minutes in both groups. RESULTS:All patients had either acute severe or life threatening asthma. The baseline characteristics were comparable in the two groups. Both groups showed significant rise in PEFR at all time intervals, however, there was no significant difference between the groups in rise in PEFR at any time point. Serum magnesium levels remained within normal limits, and there was no difference in requirement of additional medication during the study or hospital admission rates in both groups. No significant side effects were noted. CONCLUSION: This study suggests that there is no therapeutic benefit of adding magnesium sulphate to salbutamol nebulisation in the treatment of patients with acute severe or life threatening asthma.
RCT Entities:
OBJECTIVE: To test the hypothesis that combined administration of multiple doses of nebulised salbutamol and magnesium sulphate provides additional benefit compared with salbutamol alone in adult patients with acute asthma. DESIGN: Randomised, double blind, prospective study. METHODS: A total of 100 patients presenting to an emergency department with an acute attack of bronchial asthma were randomised to two groups: nebulisation with a combination of salbutamol and magnesium sulphate (group A) and nebulisation with salbutamol only (group B). Both groups received nebulisation thrice at intervals of 20 minutes. Salbutamol and magnesium sulphate were administered in doses of 0.5 mg and 500 mg, respectively, and the solutions were made isotonic to plasma osmolality. Pulse rate, blood pressure, and peak expiratory flow rate (PEFR) were measured at baseline and at 15, 60, 75, and 120 minutes. Serum magnesium levels and blood gases were measured at 0 and 120 minutes in both groups. RESULTS: All patients had either acute severe or life threatening asthma. The baseline characteristics were comparable in the two groups. Both groups showed significant rise in PEFR at all time intervals, however, there was no significant difference between the groups in rise in PEFR at any time point. Serum magnesium levels remained within normal limits, and there was no difference in requirement of additional medication during the study or hospital admission rates in both groups. No significant side effects were noted. CONCLUSION: This study suggests that there is no therapeutic benefit of adding magnesium sulphate to salbutamol nebulisation in the treatment of patients with acute severe or life threatening asthma.
Authors: Rodney Hughes; Alexandra Goldkorn; Matthew Masoli; Mark Weatherall; Carl Burgess; Richard Beasley Journal: Lancet Date: 2003-06-21 Impact factor: 79.321
Authors: Olga Bessmertny; Robert V DiGregorio; Henry Cohen; Ellen Becker; Darrell Looney; Jonathan Golden; Lewis Kohl; Thomas Johnson Journal: Ann Emerg Med Date: 2002-06 Impact factor: 5.721
Authors: Robert A Silverman; Harold Osborn; Jeffrey Runge; E John Gallagher; William Chiang; James Feldman; Theodore Gaeta; Katherine Freeman; Bruce Levin; Noel Mancherje; Steven Scharf Journal: Chest Date: 2002-08 Impact factor: 9.410
Authors: Rachel Knightly; Stephen J Milan; Rodney Hughes; Jennifer A Knopp-Sihota; Brian H Rowe; Rebecca Normansell; Colin Powell Journal: Cochrane Database Syst Rev Date: 2017-11-28
Authors: Suzanne Schuh; Judy Sweeney; Maggie Rumantir; Allan L Coates; Andrew R Willan; Derek Stephens; Eshetu G Atenafu; Yaron Finkelstein; Graham Thompson; Roger Zemek; Amy C Plint; Jocelyn Gravel; Francine M Ducharme; David W Johnson; Karen Black; Sarah Curtis; Darcy Beer; Terry P Klassen; Darcy Nicksy; Stephen B Freedman Journal: JAMA Date: 2020-11-24 Impact factor: 56.272
Authors: Suzanne Schuh; Judy Sweeney; Stephen B Freedman; Allan L Coates; David W Johnson; Graham Thompson; Jocelyn Gravel; Francine M Ducharme; Roger Zemek; Amy C Plint; Darcy Beer; Terry Klassen; Sarah Curtis; Karen Black; Darcy Nicksy; Andrew R Willan Journal: Trials Date: 2016-05-24 Impact factor: 2.279